KES
Search
- Page Path
- HOME > Search
Original Article
- Diabetes, obesity and metabolism
- Tirzepatide and Cancer Risk in Individuals with and without Diabetes: A Systematic Review and Meta-Analysis
- A.B.M. Kamrul-Hasan, Muhammad Shah Alam, Deep Dutta, Thanikai Sasikanth, Fatema Tuz Zahura Aalpona, Lakshmi Nagendra
- Endocrinol Metab. 2025;40(1):112-124. Published online January 15, 2025
- DOI: https://doi.org/10.3803/EnM.2024.2164
- 27,925 View
- 422 Download
- 2 Web of Science
- 5 Crossref
-
Abstract
PDF
Supplementary Material
PubReader 
ePub - Background
Data on the carcinogenic potential of tirzepatide from randomized controlled trials (RCTs) are limited. Furthermore, no meta-analysis has included all relevant RCTs to assess the cancer risk associated with tirzepatide.
Methods
RCTs involving patients receiving tirzepatide in the intervention arm and either a placebo or any active comparator in the control arm were searched through electronic databases. The primary outcome was the overall risk of any cancer, and secondary outcomes were the risks of specific types of cancer in the tirzepatide versus the control groups.
Results
Thirteen RCTs with 13,761 participants were analyzed. Over 26 to 72 weeks, the tirzepatide and pooled control groups had identical risks of any cancer (risk ratio, 0.78; 95% confidence interval, 0.53 to 1.16; P=0.22). The two groups had comparable cancer risks in patients with and without diabetes. In subgroup analyses, the risks were also similar in the tirzepatide versus placebo, insulin, and glucagon-like peptide-1 receptor agonist groups. The overall cancer risk was also comparable for different doses of tirzepatide compared to the control groups; only a 10-mg tirzepatide dose had a lower risk of any cancer than placebo. Furthermore, compared to the control groups (pooled or separately), tirzepatide did not increase the risk of any specific cancer types. Despite greater increments in serum calcitonin with 10- and 15-mg tirzepatide doses than with placebo, the included RCTs reported no cases of papillary thyroid carcinoma.
Conclusion
Tirzepatide use in RCTs over 26 to 72 weeks did not increase overall or specific cancer risk. -
Citations
Citations to this article as recorded by
- Dietary and pharmacological energy restriction and exercise for healthspan extension
Maria Lastra Cagigas, Isabella De Ciutiis, Andrius Masedunskas, Luigi Fontana
Trends in Endocrinology & Metabolism.2025; 36(6): 521. CrossRef - GLP-1 receptor agonists in the context of cancer: the road ahead
Isabelle R. Miousse
American Journal of Physiology-Cell Physiology.2025; 328(6): C1822. CrossRef - Treatment of type 2 diabetes mellitus - a current view of the different drug classes and strategies for their use
Jan Brož
Vnitřní lékařství.2025; 71(3): 144. CrossRef - Repurposing glucose-lowering drugs for cancer therapy
Michaela Luconi, Giulia Cantini, Clara Crescioli
Trends in Cancer.2025; 11(7): 691. CrossRef - Impact of 1-Year Tirzepatide Use on Glycemic and Metabolic Profile in Overweight to Obese People with Type 1 Diabetes: A Systematic Review and Meta-Analysis
Deep Dutta, Abul Bashar Mohammad Kamrul-Hasan, Ritin Mohindra, Nishant Raizada
Diabetes Technology and Obesity Medicine.2025; 1(1): 289. CrossRef
- Dietary and pharmacological energy restriction and exercise for healthspan extension
Case Report
- A Case of an Adrenal Hemangioma Mimicking a Pancreatic Tail Tumor.
- Yun kyong Jeon, Ji Ryang Kim, Yong Seong An, Ji Hae Kwon, Yang Ho Kang, Seok Man Son, In Ju Kim, Yong Ki Kim
- J Korean Endocr Soc. 2008;23(1):62-65. Published online February 1, 2008
- DOI: https://doi.org/10.3803/jkes.2008.23.1.62
- 2,144 View
- 22 Download
-
Abstract
PDF
- Adrenal hemangiomas are rare non-functioning tumors that originate from the retroperitoneal organs. They are generally asymptomatic, and are usually discovered at autopsy. In 1955, Johnson and Jeppensen reported the first case of a surgically removed adrenal hemangioma. We report a case of adrenal hemangioma that mimicked a pancreatic tail tumor, as detected by computed tomography. We made a diagnosis of an adrenal hemangioma from endoscopic ultrasonography and confirmed the diagnosis following a laparascopic adrenalectomy. If one is suspicious of an adrenal hemangioma, one needs to assess the lesion from every aspect. With the advancement of diagnostic techniques in arteriography, ultrasound, and computed tomography, the frequency of preoperative recognition and diagnosis is on the increase. Still, it is difficult to diagnose an adrenal hemangioma just from an imaging study. One should consider performing surgery for removal of the tumor to rule out a malignancy, and to prevent traumatic rupture. With the case presentation, we review the clinical, radiographic, and pathological features of adrenal hemangiomas.
First
Prev
